Analysis of the main functions and clinical effects of venetoclax/venetoclax (venetoclax)

Venetoclax (Venetoclax) is an oral targeted drug that mainly works by selectively inhibiting the BCL-2 protein. BCL-2 is a protein that inhibits apoptosis. In many blood tumors, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), BCL-2 is overexpressed, causing cancer cells to escape apoptosis. By inhibiting BCL-2, venetoclax can promote programmed death of cancer cells, thereby achieving the effect of inhibiting tumors.

Clinically, venetoclax is mainly used to treat certain types of hematological malignancies. For patients with chronic lymphocytic leukemia with 17p deletions or TP53 mutations, venetoclax has shown significant efficacy, extending progression-free survival and improving overall response rates. At the same time, it can also be combined with other drugs, such as rituximab or low-dose chemotherapy regimens, to further improve the therapeutic effect.

The clinical advantages of venetoclax are its strong targeting and controllable side effects. Compared with traditional chemotherapy, its main side effects include cytopenias, risk of infection, and tumor lysis syndrome. However, through gradual escalation and standardized monitoring, these risks can usually be effectively managed. In addition, oral administration also improves patients' medication compliance and life convenience.

In summary, venetoclax, as an innovative drug targetingBCL-2, provides an effective treatment option for patients with high-risk hematological tumors. By precisely intervening in the apoptosis pathway, it can eliminate cancer cells in a targeted manner while providing patients with a safer and more controllable treatment plan. In future clinical applications, combined treatments and personalized programs are expected to further enhance its efficacy and scope of application.

Reference materials:https://www.drugs.com/